Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

Effect of Furin inhibitor on lung adenocarcinoma cell growth and metastasis

Authors: Yong-Chao Ma, Wen-Juan Fan, Shu-Mei Rao, Li Gao, Zhan-Yu Bei, Song-Tao Xu

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Background

To investigate the mechanisms of lung adenocarcinoma cell metastasis and provide a theoretical basis for the in-depth study of lung adenocarcinoma.

Methods

A549 cells are incubated with different concentrations of Furin inhibitor for indicated times. The proliferation and migration were confirmed with MTT, colony formation, wound Healing and Transwell assayes. Hochest 33342 / PI double staining was used to detect apoptosis. Cell migration and apoptosis associated proteins were analysed by enzyme-linked immunosorbent assay (ELISA) and western blot.

Results

We have found that Furin inhibitor play a significant role in inhibition A549 cell growth. And we also found cell migration was inhibited significantly upon Furin inhibitor treatment.

Conclusion

The proliferration and migration of A549 cell were inhibited by Furin inbitor through down-regulation the expression of migration and apoptosis related proteins.
Appendix
Available only for authorised users
Literature
1.
Weir HK, Thun MJ, Hankey BF: Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003, 95 (17): 1276-1299. 10.1093/jnci/djg040.CrossRefPubMed
2.
Sakashita S, Sakashita M, Sound Tsao M: Genes and pathology of non-small cell lung carcinoma. Semin Oncol. 2014, 41 (1): 28-39. 10.1053/j.seminoncol.2013.12.008.CrossRefPubMed
3.
4.
Basak A, Chen A, Scamuffa N, Mohottalage D, Basak S, Khatib AM: Blockade of furin activity and furin-induced tumor cells malignant phenotypes by the chemically synthesized human furin prodomain. Curr Med Chem. 2010, 17 (21): 2214-2221. 10.2174/092986710791331040.CrossRefPubMed
5.
Couture F, D'Anjou F, Desjardins R, Boudreau F, Day R: Role of proprotein convertases in prostate cancer progression. Neoplasia. 2012, 14 (11): 1032-1042.CrossRefPubMedCentralPubMed
6.
Lalou C, Basak A, Mishra P, Mohanta BC, Banik R, Dinda B, Khatib AM: Inhibition of tumor cells proliferation and migration by the flavonoid furin inhibitor isolated from Oroxylum indicum. Curr Med Chem. 2013, 20 (4): 583-591.PubMed
7.
Cavallar U, Christofori G: Multitasking in tumor progression: signaling function of cell adhension molecules. Ann N YAcad Sci. 2004, 10 (14): 58-66.CrossRef
8.
Bassi DE, Mahloogi H, Al-Saleem L: Elevated Furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog. 2001, 31 (4): 224-232. 10.1002/mc.1057.CrossRefPubMed
9.
Scamuffa N, Sfaxi F, Ma J, Lalou C, Seidah N, Calvo F, Khatib AM: Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis. Carcinogenesis. 2014, 35 (3): 528-536. 10.1093/carcin/bgt345.CrossRefPubMed
10.
Mbikay M, Sirois F, Yao J: Comparative analysis of expression of the proprotein convertases furin, PACE4, PCI and PC2 inhuman lung tumours. Br J Cancer. 1997, 75 (10): 1509-1514. 10.1038/bjc.1997.258.CrossRefPubMedCentralPubMed
11.
Gao J, Ding F, Liu Q, Yao Y: Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem. 2012, 12: 1545-1557.
12.
Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ: Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell. 2003, 114 (1): 33-45. 10.1016/S0092-8674(03)00513-0.CrossRefPubMed
13.
Rozanov DV, Golubkov VS, Strongin AY: Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin. Int J Biochem Cell Biol. 2005, 37 (1): 142-154. 10.1016/j.biocel.2004.06.005.CrossRefPubMed
14.
Stacker SA, Caesar C, Baldwin ME: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001, 7: 186-191. 10.1038/84635.CrossRefPubMed
15.
Nagy JA, Vasile E, Feng D: Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002, 196: 1497-1506. 10.1084/jem.20021244.CrossRefPubMedCentralPubMed
16.
Voura EB, English JL, Yu HY, Ho AT, Subarsky P, Hill RP, Hojilla CV, Khokha R: Proteolysis during tumor cell extravasation in vitro: metalloproteinase involvement across tumor cell types. PLoS One. 2013, 8 (10): e78413-10.1371/journal.pone.0078413.CrossRefPubMedCentralPubMed
Metadata
Title
Effect of Furin inhibitor on lung adenocarcinoma cell growth and metastasis
Authors
Yong-Chao Ma
Wen-Juan Fan
Shu-Mei Rao
Li Gao
Zhan-Yu Bei
Song-Tao Xu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-14-43

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue

Primary research

Interleukin-23A is associated with tumor growth in Helicobacter-pylori-related human gastric cancer

Primary research

Clinical and laboratory features of seven patients with acute myeloid leukemia (AML)-M2/M3 and elevated myeloblasts and abnormal promyelocytes

Primary research

Myricetin enhance chemosensitivity of 5-fluorouracil on esophageal carcinoma in vitro and in vivo

Primary research

The association between hypoxia-inducible factor-1 α gene G1790A polymorphism and cancer risk: a meta-analysis of 28 case–control studies

Primary research

The mitochondrial ATPase6 gene is more susceptible to mutation than the ATPase8 gene in breast cancer patients

Primary research

Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits